CDKL5 Deficiency Disorder Voice of the Patient Report Submitted to FDA

Understanding the patient voice is fundamental for therapy development. Companies need to ensure that what matters most to patients is being assessed, and regulators and payers asks for demonstration of value to support approval and reimbursement. Today, the Loulou Foundation and the International Foundation for CDKL5 Research (IFCR) are proud to release the “CDKL5 Deficiency Disorder Voice of the Patient Report”, capturing the voice of patients living with this rare genetic disease that affects thousands of people.

The report is the outcome of a groundbreaking patient-centered meeting …

Read More
IFCR & RDMD Partner to Accelerate Drug Development

You can accelerate drug development in CDKL5 (CDKL5 deficiency disorder)

Important research records are trapped in hospitals across the country. As a result, drug researchers can’t access the information they need to advance treatments.

But as a patient caregiver, you can. Unlock your records and contribute them to research, privately and securely.

Read More
Marinus Announces Completion of Marigold Trial

Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder

“Enrolling 100 patients in our registrational, pivotal Phase 3 trial evaluating ganaxolone in children with CDD is a significant milestone for both Marinus and the CDD community,” said Joe Hulihan, M.D., Chief Medical Officer of Marinus. “Our ability to identify and rapidly enroll qualified patients into this study is indicative of the significant need for a new therapy to reduce seizure burden and improve patient outcomes. The study has been well conducted and we are encouraged by the limited adverse events, low dropout rates and the vast majority of patients entering the open-label extension. We are appreciative of the patients and broader CDD community for their participation in the Marigold study and we remain committed to addressing the unmet need of these patients who currently have no approved treatment options.”

Read More
2019 AES Thought Leader Theatre

Thought Leader Theatre

IFCR President, Karen Utley, joins Eisai host Kimberly Bottom for the 2019 AES Thought Leader Theatre at the 2019 American Epilepsy Society Meeting to talk about our organization and CDKL5 Deficiency.

Read more to watch the video!


Read More
CDKL5 Deficiency Receives ICD-10-CM code: G40.42

ICD-10-CM code for CDD Approved!

Together with the Loulou Foundation and the directors of the CDKL5 Centers of Excellence, we submitted a proposal for the creation of a new ICD-10-CM code for CDKL5 Deficiency Disorder (CDD) that was reviewed during the September 11 meeting and is currently receiving comments until November 8, 2019. It is a pleasure to announce that the application to create a new ICD-10-CM code for CDD: G40.42 Cyclin-Dependent Kinase-Like 5 Deficiency Disorder, CDKL5 was approved.

Read More
CDKL5 Forum 2019

The CDKL5 Forum is an annual “by-invite-only” event hosted by the Loulou Foundation to report on the progression of the CDKL5 Deficiency Disorder field. IFCR board members, Rick Upp and Amanda Jaksha, and Science Director, Heidi Grabenstatter, attended this event that includes scientists, industry representatives, clinicians, and nonprofit leaders invested specifically in CDKL5 Deficiency Disorder (CDD). It was clear that the rapid progress occurring in CDD research …

Read More
For Families
Get Involved